Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979807 · ClinicalTrials.gov registry record
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 11,296
- Enrollment target
NCT03979807: Completed study, sponsored by Boehringer Ingelheim.
NCT03979807 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 11,296 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03979807 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 11,296 participants
- Enrollment target
Study Summary
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
Primary Outcome
The primary outcome of interest was discontinuation of index treatment (Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol), defined as persistence, (i.e. no refill Claim within 60 days \[not including treatment Switch, nor death\] after end of supply) during follow-up. Persistence was assessed by calculating rates of discontinuation in the matched cohorts using a 60-day allowable gap. Rates of discontinuation are reported as the number of events divided by the number of Person-years at ri
Interventions
- DRUG Umeclidinium/ Vilanterol
- DRUG Olodaterol/Tiotropium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,296 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2019-06-11 |
What the finished NCT03979807 record still lists
NCT03979807 is an observational study that tracks outcomes without assigning an intervention. Its 11,296 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Umeclidinium/ Vilanterol is the first listed.
NCT03979807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03979807 about?
NCT03979807 is a clinical study titled "A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)". To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
What is the current status of trial NCT03979807?
This trial is currently completed. The enrollment target is 11,296 participants. The study started on 2019-06-10. Estimated completion is 2019-06-11.
What interventions are being tested in trial NCT03979807?
The interventions under investigation include: Umeclidinium/ Vilanterol (DRUG), Olodaterol/Tiotropium Bromide (DRUG).
Who is sponsoring clinical trial NCT03979807?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI